+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Perrigo Co Plc (PRGO) - Financial and Strategic SWOT Analysis Review

Perrigo Co Plc (PRGO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Perrigo Co Plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic, specialty pharmaceutical company, nutritional products, and infant formulas and foods. The company’s major products include analgesics, gastrointestinal, personal care and derma therapeutics, clobetasol spray, clindamycin foam, mupirocin ointment, Ketoconazole, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drugs, supermarket and mass merchandise chains and direct sales representatives. The company has operational presence in various geographical regions such as Australia, Israel and China. Perrigo is headquartered in Dublin, Ireland.

Perrigo Co Plc Key Recent Developments

  • Feb 27, 2023: Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations
  • Nov 08, 2022: Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations
  • Oct 27, 2022: Perrigo receives notification of postponement for joint FDA advisory committee to review Opill daily oral contraceptive for over-the-counter (OTC) use
  • Aug 09, 2022: Perrigo Reports Second Quarter Fiscal Year 2022 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Perrigo Co Plc - Key Facts
  • Perrigo Co Plc - Key Employees
  • Perrigo Co Plc - Key Employee Biographies
  • Perrigo Co Plc - Major Products and Services
  • Perrigo Co Plc - History
  • Perrigo Co Plc - Company Statement
  • Perrigo Co Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Perrigo Co Plc - Business Description
  • Business Segment: Consumer Self-Care Americas
  • Overview
  • Performance
  • Business Segment: Consumer Self-Care International
  • Overview
  • Performance
  • Geographical Segment: All Other Countries
  • Target Markets
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: U.S.
  • Performance
  • R&D Overview
  • Perrigo Co Plc - Corporate Strategy
  • Perrigo Co Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Perrigo Co Plc - Strengths
  • Perrigo Co Plc - Weaknesses
  • Perrigo Co Plc - Opportunities
  • Perrigo Co Plc - Threats
  • Perrigo Co Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Perrigo Co Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 27, 2023: Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations
  • Nov 08, 2022: Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations
  • Oct 27, 2022: Perrigo receives notification of postponement for joint FDA advisory committee to review Opill daily oral contraceptive for over-the-counter (OTC) use
  • Aug 09, 2022: Perrigo Reports Second Quarter Fiscal Year 2022 Financial Results
  • Jun 01, 2022: PERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER
  • May 19, 2022: Perrigo To Present At Upcoming Consumer Investor Conferences
  • Apr 20, 2022: Perrigo announces closing of $2.6 billion senior secured credit facilities
  • Apr 04, 2022: Fitch Rates Perrigo Investments LLC's Proposed Senior Unsecured Notes ''BB+(EXP)''/''RR4''
  • Mar 24, 2022: PERRIGO ANNOUNCES CFO RETIREMENT AND TRANSITION PLAN
  • Mar 01, 2022: Perrigo Reports Fourth Quarter & Fiscal Year 2021 Financial Results From Continuing Operations
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Perrigo Co Plc, Key Facts
  • Perrigo Co Plc, Key Employees
  • Perrigo Co Plc, Key Employee Biographies
  • Perrigo Co Plc, Major Products and Services
  • Perrigo Co Plc, History
  • Perrigo Co Plc, Subsidiaries
  • Perrigo Co Plc, Key Competitors
  • Perrigo Co Plc, Ratios based on current share price
  • Perrigo Co Plc, Annual Ratios
  • Perrigo Co Plc, Interim Ratios
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Perrigo Co Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Perrigo Co Plc, Performance Chart (2018 - 2022)
  • Perrigo Co Plc, Ratio Charts
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Viatris Inc
  • The Procter & Gamble Co
  • Teva Pharmaceutical Industries Ltd
  • Taro Pharmaceutical Industries Ltd
  • Stada Arzneimittel AG
  • Sanofi
  • Sandoz Inc
  • Reckitt Benckiser Group Plc
  • Pfizer Inc
  • Novartis International AG
  • Lupin Ltd
  • LNK International Inc
  • Koninklijke Philips NV
  • Johnson & Johnson
  • Glenmark Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Inc
  • Bayer AG
  • Aurobindo Pharma Ltd
  • Abbott Laboratories
  • Sandoz Inc
  • Pfizer Inc
  • Sanofi
  • Abbott Laboratories
  • Reckitt Benckiser Group Plc
  • Glenmark Pharmaceuticals Inc
  • Bayer AG
  • The Procter & Gamble Co
  • Lupin Ltd
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd
  • Taro Pharmaceutical Industries Ltd
  • Stada Arzneimittel AG
  • Novartis International AG
  • Dr. Reddy's Laboratories Inc
  • Koninklijke Philips NV
  • Viatris Inc
  • LNK International Inc
  • Aurobindo Pharma Ltd